Commentary: Intravenous Immunoglobulin (IVIG) Therapy for Patients with Langerhans Cell Histiocytosis (LCH)-Related Neurodegenerative Diseases of the CNS

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 14, Iss. 6, 2015-08 ,pp. : 688-690

Bentham Science Publishers

Access to resources Recommend Favorite

Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma

By Chen Yi-Bin   Batchelor Tracy   Li Shuli   Hochberg Ephraim   Brezina Mark   Jones Sooae   Del Rio Candice   Curtis Morgan   Ballen Karen K.   Barnes Jeffrey   Chi Andrew S.   Dietrich Jorg   Driscoll Jessica   Gertsner Elizabeth R.   Hochberg Fred   LaCasce Ann S.   McAfee Steven L.   Spitzer Thomas R.   Nayak Lakshmi   Armand Philippe  

Cancer, Vol. 121, Iss. 2, 2015-01 ,pp. : 226-233

Blackwell Publishing

Access to resources Recommend Favorite

Treatment of Central Nervous System Involvement Associated with Primary Sjogren's Syndrome

By  

Current Pharmaceutical Design, Vol. 14, Iss. 13, 2008-05 ,pp. : 1270-1273

Bentham Science Publishers

Access to resources Recommend Favorite

Drug therapy for the treatment of Langerhans cell histiocytosis

By McClain Kenneth L  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 14, 2005-11 ,pp. : 2435-2441

Informa Healthcare

Access to resources Recommend Favorite

Clonal Status and Clinicopathological Features of Langerhans Cell Histiocytosis

By Gong L   Zhang W-D   Li Y-H   Liu X-Y   Yao L   Han X-J   Zhu S-J   Lan M   Zhang W  

The Journal of International Medical Research, Vol. 38, Iss. 3, 2010-06 ,pp. : 1099-1105

Field House Publishing

Access to resources Recommend Favorite